U.S. Markets open in 3 hrs 13 mins
  • S&P Futures

    4,538.50
    +30.00 (+0.67%)
     
  • Dow Futures

    34,284.00
    +282.00 (+0.83%)
     
  • Nasdaq Futures

    15,934.75
    +65.00 (+0.41%)
     
  • Russell 2000 Futures

    2,168.80
    +22.50 (+1.05%)
     
  • Crude Oil

    66.77
    +1.20 (+1.83%)
     
  • Gold

    1,777.00
    -7.30 (-0.41%)
     
  • Silver

    22.32
    +0.02 (+0.09%)
     
  • EUR/USD

    1.1342
    +0.0019 (+0.1701%)
     
  • 10-Yr Bond

    1.4340
    0.0000 (0.00%)
     
  • Vix

    28.34
    +1.15 (+4.23%)
     
  • GBP/USD

    1.3327
    +0.0049 (+0.3718%)
     
  • USD/JPY

    112.9780
    +0.1980 (+0.1756%)
     
  • BTC-USD

    56,231.72
    -757.83 (-1.33%)
     
  • CMC Crypto 200

    1,432.51
    -36.57 (-2.49%)
     
  • FTSE 100

    7,127.86
    -40.82 (-0.57%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Novavax, Inc. (NVAX) Investigation

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / October 22, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Investors who purchased Novavax shares are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/nvax.

The investigation concerns whether Novavax and certain of its officers and/or directors have violated federal securities laws.

Earlier this summer Novavax announced that it expected to seek regulatory approval from the U.S. Food & Drug Administration for its coronavirus vaccine candidate in the fourth quarter, and that it planned to reach a manufacturing capacity of 100 million doses per month by October and 150 million does per month by the end of the year. On October 20, 2021, Politico reported that Novavax was short of production targets due in part to issues linked to testing the 'purity' of its NVX-CoV2373. Following this news, Novavax dropped to a low of $121.35 per share, during intra-day trading on October 20, 2021.

If you are aware of any facts relating to this investigation, or purchased Novavax shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/nvax. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/669227/Bronstein-Gewirtz-Grossman-LLC-Reminds-Shareholders-of-Novavax-Inc-NVAX-Investigation